Influenza virus immunogenicity composition and application thereof

Abstract

The invention discloses an influenza virus immunogenicity composition and application thereof. The composition comprises the following components in percentage by weight: 3-8% of ribonucleic acid, 0.3-1% of desoxyribonucleic acid, 0.7-1.5% of oligonucleotides, 0.9-3.2% of polynucleotide, 0.6-2.3% of pentose, 1.2-1.5% of fusion protein, 1-4% of thymine, 1.2-4.3% of cytosine, 0.8-1.5% of antiviral polypeptide, 1.1-3.7% of cell factor simulation peptide, 0.4-2.8% of small molecular active polypeptide, 0.6-1.5% of 8-type capsular polysaccharide, 0.2-0.5% of Pn-serum type 12F, 1.2-1.8% of lactic acid, 0.2-0.4% of glycollic acid, 0.15-0.3% of polysorbate, 0.1-0.2% of sorbitan trioleate and the balance of a polysaccharide solution. The composition disclosed by the invention is capable of efficiently preventing influenza viruses and greatly improving prevention efficiency, and is simple in processing method and worthy of popularization; the problem of hysteresis quality of a conventional drugfor viruses is solved, and the viruses cannot resist and upgrade after the composition is used.

Description

technical field [0001] The invention relates to the technical field of pharmaceutical compositions, in particular to an influenza virus immunogenic composition and its application. Background technique [0002] Influenza (abbreviated as influenza) is an acute respiratory infection caused by influenza virus, and it is also a disease with strong contagion and fast transmission speed. It is mainly spread through droplets in the air, person-to-person contact or contact with contaminated items. Typical clinical symptoms are: sudden onset of high fever, general pain, significant fatigue and mild respiratory symptoms. Generally, autumn and winter are the high-incidence period, and the complications and death caused by it are very serious. The disease is caused by influenza virus, which can be divided into three types: A (A), B (B), and C (C). Type A virus often undergoes antigenic variation, is highly contagious, spreads rapidly, and is very prone to large-scale epidemics. Type ...

AI Technical Summary

Problems solved by technology

[0003] At present, the drugs for preventing influenza virus, due to the continuous upgrading of the virus, often lead to a lag in the prevention effect. It is necessary to continuously develop new drugs for prevention, which consumes a lot of research, and the prevention effect is poor. In view of the above, we propose an influenza virus immunogen Sexual composition and its application